We see the unseen.
At Alexion, we see opportunities where others do not and we have the courage to explore what others believe is impossible. We see patients suffering from devastating diseases that are often overlooked. We see a pathway from innovative science to the delivery of breakthrough therapies.
Patients with these life-threatening diseases often have no effective treatment options, and they and their families suffer with little hope. Our goal is to deliver medical breakthroughs where none currently exist. We are driven because we know people's lives depend on our work.
Welcome to the Alexion Australasia website. The Sydney office was established in 2008 and is responsible for Australia, New Zealand and the Asia Pacific region. We are a small team of dedicated professionals committed to providing life-transforming treatments to patients with severe and life-threatening rare diseases for which there are few, if any, effective treatment options.
In Australia, Soliris® (eculizumab, rmc) is registered by the Therapeutics Goods Administration (TGA) for the treatment of paroxysmal nocturnal haemoglobinuria (PNH) and atypical haemolytic uraemic syndrome (aHUS). Soliris has been funded via the Life Saving Drugs Program for PNH since 1st January 2011 and via the Section 100 Highly Specialised Drugs Program for aHUS from 1st December 2014. Both PNH and aHUS are ultra-rare diseases that are severe, chronic and progressive, with high mortality and morbidity rates and a profound impact on patients, their families and society.
Alexion employees in Australia Join Colleagues Around the World for Global Day of Service
On September 23, 2016, more than 1,500 Alexion employees volunteered in their local communities as part of the Company’s first Global Day of Service. The event helped inspire and connect employees with a common purpose and brought hands-on support to some of the most pressing needs in our local neighborhoods. Employees in Australia partnered with the Aspect Vern Barnett School, which is a not for profit school for Autistic Children. Read the press release to learn more.
Strensiq Approved by TGA for Patients with Paediatric-Onset HPP
In January 2016, the Therapeutic Goods Administration (TGA) approved Strensiq® (asfotase alfa) for the treatment of patients with paediatric-onset hypophosphatasia (HPP). The approval is important news for patients in Australia who suffer from this rare, serious and potentially fatal genetic disorder. Alexion is working with the Pharmaceutical Benefits Advisory Committee (PBAC) to prepare a submission for Strensiq to be listed on the Pharmaceutical Benefits Schedule.
Access to Soliris Extended to 24 Months for Patients with aHUS
On December 17, Health Minister Sussan Ley accepted the Pharmaceutical Benefits Advisory Committee (PBAC) recommendation to extend access to Soliris® (eculizumab, rmc) for patients with atypical haemolytic uraemic syndrome (aHUS) to 24 months.
This decision is good news for patients and their families who were extremely concerned about stopping treatment. Alexion is committed to continuing to work with the government to provide a long-term solution that is in the best interest of patients suffering from this rare and devastating disease.